Skip to main content

Drug Interaction Report

1 potential interaction and/or warning found for the following 2 drugs:

Add another drug
Filter by interaction and/or warning

Interactions between your drugs

Moderate

immune globulin intravenous ravulizumab

Applies to: Panglobulin NF (immune globulin intravenous), ravulizumab

ADJUST DOSE: Intravenous immunoglobulin (IVIg) treatment has been shown to decrease ravulizumab systemic concentrations. IVIg treatment may interfere with the endosomal neonatal Fc receptor (FcRn) recycling mechanism of monoclonal antibodies such as ravulizumab, which may lead to decreased serum concentrations. Drug interaction studies have not been conducted with ravulizumab in patients treated with IVIg.

MANAGEMENT: The manufacturer advises a supplemental dose of ravulizumab be administered to patients receiving IVIg treatment. For patients weighing 40 kg or more, they recommend a 600 mg supplemental dose of ravulizumab be administered within 4 hours following completion of an IVIg cycle. The manufacturer's product labeling should be consulted for further information.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2019) "Product Information. Ultomiris (ravulizumab)." Alexion Pharmaceuticals Inc

Drug and food interactions

No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer